Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Ivermectin (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors MedinCell S.A.
- 19 Apr 2021 Status changed from recruiting to completed, according to a MedinCell S.A. media release.
- 19 Apr 2021 Preliminary results presented in a MedinCell S.A. media release.
- 05 Mar 2021 According to a MedinCell media release, the company is currently completing a clinical trial aiming at demonstrating the safety of ivermectin when taken daily in oral form in order to simulate the continuous release of the drug by a long-acting injectable, full results from this study will be made available in the coming weeks which will support the regulatory review of this long-acting injectable formulation.